Listing & Compliance Notices

WeWork Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“April 12, 2023 , WeWork Inc. (the “Company”) received notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that as of April 11, 2023 it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”) because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice has no immediate impact on the listing of the Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other”

Spark Networks SE received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 12, 2023, Spark Networks SE (the “Company”) received a written notice from Nasdaq (the “Notice”) dated April 12, 2023, notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2.5 million. In the Company’s Annual Report on Form 10-K for the fourth quarter and year ended December 31, 2022, the Company reported stockholders’ deficit of approximately $(6,786,000), which is below the minimu”

AIRWA INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 12, 2023, Nasdaq notified the Company that the Panel had granted the Company’s request for continued listing on the Nasdaq had been granted subject to the following: 1. On or before May 31, 2023, the Company shall file the delinquent Form 10-K for the year ended April 30, 2022, with the SEC; 2. On or before June 30, 2023, the Company shall file all delinquent Forms 10-Q with the SEC; 3. On or before July 15th, the Company will demonstrate compliance with Listing Rules 5605(b)(1), 5605(c)(2) and 5605(d)(2) (majority independent director, audit committee and compensation committee composit”

CONTRAFECT Corp received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“April 12, 2023, ContraFect Corporation (the “Company”) received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) had granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to the Company evidencing compliance with all applicable criteria for continued listing, including the $2.5 million minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) (the “Rule”), by no later than June 30, 2023 (the “Compliance Period”). The Company’s continued listing during the Compliance P”

CAMBER ENERGY, INC. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).

“April 12, 2023, Camber Energy Inc. (the “ Company ”) received a deficiency letter (the “ Deficiency Letter ”) from the NYSE American LLC (the “ NYSE American ”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide. Section 1003(a)(i) of the NYSE American Company Guide requires a listed company’s stockholders’ equity be at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. Section 1”

FLOTEK INDUSTRIES INC/CN/ received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“April 12, 2023, Flotek Industries, Inc. (the “Company”) received written notice from the New York Stock Exchange (the “NYSE”) notifying it that the average closing price of the Company’s common stock over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the NYSE under Item 802.01C of the NYSE Listed Company Manual. In accordance with applicable NYSE procedures, the Company plans to notify the NYSE of its intent to cure the $1.00 per share deficiency. Based on the applicable NYSE procedures, the Company has six months following t”

DMK PHARMACEUTICALS Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 12, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that for the last 30 consecutive business days, the Company’s minimum Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). The Notice is only a notification of deficiency, not of imminent delisting”

Eightco Holdings Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“Market LLC (“NASDAQ”) stating that the Company was not in compliance with the minimum bid price requirement of $1.00 per share set forth in NASDAQ Rules for continued listing on NASDAQ. The Company was provided 180 calendar days, or until April 3, 2023, to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). To regain compliance, the shares of the Company’s common stock must have had a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. On April 11, 2023, the Company received a Staff Determination (the “Determination”) that the Company did”

Ouster, Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“April 12, 2023, the Company was notified by the New York Stock Exchange (the “ NYSE ”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual (“ Section 802.01C ”) because the average closing price of the Company’s common stock, over a consecutive 30 trading-day period, was less than $1.00 (the “ NYSE Notification ”). The Company notified the NYSE of its intent to effect a reverse stock split prior to receipt of the NYSE Notification and the Company plans to notify the NYSE of its intent to cure the stock price deficiency and return to compliance with the NYSE cont”

Satsuma Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“notifying the Company that, for the 30 consecutive business day period between February 27, 2023 through April 10, 2023, the Company’s Common Stock, had not maintained a minimum bid price of $1.00 per share, required for continued listing on the Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Price Requirement ”). Nasdaq’s written notice does not result in the immediate delisting of the Common Stock from the Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “ Compliance Period Rule ”), the Company has 180 calendar days, or until”

Nxu, Inc. received a nasdaq deficiency notice notice regarding minimum bid price.

“April 11, 2023, the Company received the Notice indicating that the Company is not in compliance with the Bid Price Requirement. The Notice has no immediate effect on the listing of the Company’s Class A common stock on Nasdaq and the Company will have 180 calendar days from the date of the Notice in which to regain compliance with the Bid Price Requirement. As a result, the date by which the Company has to regain compliance with the Bid Price Requirement is October 8, 2023. If at any time prior to October 8, 2023, the bid price of the Company’s common stock closes at or above $1.00 per share”

LM FUNDING AMERICA, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 14, 2023, LM Funding America, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s consolidated closing bid price has been below $1.00 per share for 30 consecutive business days as of April 13, 2023, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which is the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule”

IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(C)).

“April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum”

IMPEL PHARMACEUTICALS INC received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

“April 11, 2023, Impel Pharmaceuticals Inc. (the “Company”) received two written notifications from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”). The first notification indicated that as of April 11, 2023, the Company did not meet the $15,000,000 minimum market value of publicly held shares required to maintain continued listing as set forth in Nasdaq Marketplace Rule 5450(b)(2)(C) (the “MVPHS Rule”) for the 30-business day period ended April 5, 2023. The second notification indicated that as of April 11, 2023, the Company did not meet the $50,000,000 minimum”

CDT Equity Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“April 10, 2023, Murphy Canyon Acquisition Corp. (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) that, for the previous 30 consecutive business days, the Market Value of Listed Securities (“MVLS”) for the Class A Common Stock of the Company, par value $0.0001 per share (“ Class A Common Stock ”), was below the $50 million minimum MVLS requirement for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Rule ”). The Letter is only a notification of deficiency”

Roth CH Acquisition Co. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“April 11, 2023, TKB Critical Technologies 1 (the “Company”) received a letter (the “MVPHS Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive trading days prior to the date of the MVPHS Notice, the Company’s minimum market value of publicly held shares was less than $15.0 million, which does not meet the requirement for continued listing on The Nasdaq Global Market, as required by Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Rule”). On April 13, 2023, the Company demonstrated complia”

Wheels Up Experience Inc. received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“April 12, 2023, Wheels Up Experience Inc. (the “Company”) received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is no longer in compliance with Section 802.01C of the NYSE Listed Company Manual (“Section 802.01C”), which requires listed companies to maintain an average closing price per share of at least $1.00 over a 30 consecutive trading-day period. Pursuant to Section 802.01C, the Company has a period of six months after receipt of the Notice (the “Cure Period”) to regain compliance. As of the date of this Current Report on Form 8-K, the Company is in compli”

Applied UV, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 12, 2023, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until October 10, 2023 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by October 10, 2023, the Company may be eligible for an additional 180-day period”

Vinco Ventures, Inc. received a nasdaq extension granted notice regarding other (rules 5250(c)(1), 5810(c)).

“April 14, 2023, Vinco Ventures, Inc. (the “Company”) received a letter from the Nasdaq stating that The Nasdaq Hearings Panel (“Panel”) grants the request of Vinco Ventures, Inc. (the “Company”) to continue its listing on The Nasdaq Stock Market (“Nasdaq” or the “Exchange”), subject to compliance with the following: 1. On April 27, 2023, the Company shall regain compliance with the Shareholders Meeting Rule by holding its Annual Shareholders Meeting on that date; and 2. On or before July 7, 2023, the Company shall demonstrate compliance with the filing requirements in the Periodic Filing Rule”

Virpax Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 10, 2023, Virpax Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pric”

Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“April 11, 2023, Applied Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. Pursuant to Nasdaq”

Phunware, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 13, 2023, Phunware, Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”) because the bid price of the Company’s common stock on the Nasdaq Capital Market had closed below $1.00 per share for the previous 30 consecutive business days. The notice received has no immediate effect on the Company's Nasdaq listing. The notice from Nasdaq states that, under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days”

Grom Social Enterprises, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 10, 2023, Grom Social Enterprises, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minim”

Myseum.AI, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“April 13, 2023, the Company was notified (the “Second Notification Letter”) by the Staff that the Company is eligible for an additional 180 calendar day period, or until October 9, 2023 to regain compliance and cure the deficiency, so long as the Company meets the Nasdaq continued listing requirements (except for the bid price requirement). The Second Notification Letter has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market and, at this time, the common stock will continue to trade on the Nasdaq Capital Market under the symbol “DATS.” If t”

Vroom, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(H)).

“April 14, 2023, Vroom, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing of the Common Stock, which continues to trade on the Nasdaq Global Select Mark”

Cepton, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 13, 2023, Cepton, Inc. (the “ Company ”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that, for the 30 consecutive business day period beginning March 1, 2023 and ending April 12, 2023, the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market”

ATHERSYS, INC / NEW received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(b)(2)).

“April 13, 2023, the Company received written notification (the “Notification”) from Nasdaq stating that the Company had not regained compliance with the Market Value Standard. Pursuant to the Notification, the Common Stock is subject to delisting from Nasdaq pending the Company’s opportunity to request a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to diligently pursue an appeal of the Notification before the Panel and regain compliance with the Rule. Under Nasdaq rules, the delisting of the Common Stock will be stayed during the pendency of the appeal and during”

Eloxx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 11, 2023, Eloxx Pharmaceuticals, Inc. (the “ Company ”) received a determination letter (the “ Letter ”) from the staff (the “ Staff ”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company has not regained compliance with Listing Rule 5550(b)(2) (the “ Minimum Market Value Requirement ”), requiring the Company to maintain a Market Value of Listed Securities of a minimum of $35 million, during the 180-day grace period previously granted to the Company. As previously disclosed, the Company was initially notified by the Staff on Octob”

LIFECORE BIOMEDICAL, INC. DE received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“April 13, 2023, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the period ended February 26, 2023 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). The notification letter has no immediate”

NextTrip, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules IM-5101-1).

“April 13, 2023, Nasdaq notified us that the Nasdaq Staff has granted us an additional 180 calendar day period, or until October 9, 2023, to regain compliance based on our meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the bid price requirement, and our written notice of our intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. According to Nasdaq’s notice, if at any time during this addi”

Technology & Telecommunication Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“April 11, 2023, Technology & Telecommunication Acquisition Corporation (the “ Company ”) received a letter (the “ MVLS Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Minimum Market Value of Listed Securities (“ MVLS ”) was less than $50.0 million, which does not meet the requirement for continued listing on The Nasdaq Global Market, as required by Nasdaq Listing Rule 5450(b)(2)(A) (the “ MVLS Rule ”). In accor”

Global System Dynamics, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“April 5, 2022, Global System Dynamics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the $35 million minimum requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). The notification received has no immediate effect on the Company’s Nasdaq listing. In accordance with Nasdaq rules”

SURGALIGN HOLDINGS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)(2), 5450(b)(3)).

“April 10, 2023, Surgalign Holdings, Inc. (the “Company”) received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A). Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies to maintain stockholders’ equity of at least $10,000,000 (the “Stockholders’ Equity Requirement”). The Staff further indicated that, as of the date of the Letter, the Co”

PepperLime Health Acquisition Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(D)).

“April 6, 2023, PepperLime Health Acquisition Corporation (the “ Company ”) received a second notice (the “ MVLS Notice ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”), stating that the Company’s listed securities failed to comply with the $50 million market value of listed securities (“ Market Value of Listed Securities ”) requirement for continued listing on the Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(A) based upon the Company’s Market Value of Listed Securities for the 30 consecutive business days prior to the date of the MVLS Notice. The MVLS Notice has no im”

Allarity Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5450(b)(1)(A)).

“April 11, 2023, we received notification from the Nasdaq Listing Qualifications staff that it has determined that the Company did not meet the terms of the extension. Specifically, the Company did not complete its proposed transactions and was unable to file a Form 8-K by the April 10, 2023 deadline, evidencing compliance with the Rule. As a result, the Company’s securities will be delisted from The Nasdaq Global Market. In that regard, unless the Company requests an appeal of such determination, trading of the Company’s Common Stock will be suspended at the opening of business on April 20, 20”

QT IMAGING HOLDINGS, INC. received a nyse delisting notice notice regarding market value (rules 802.01B).

“April 6, 2023, the New York Stock Exchange (the “ NYSE ”) announced that the staff of NYSE Regulation has determined to commence proceedings to delist the units, common stock and warrants of GigCapital5, Inc. (“GigCapital5”) from the NYSE pursuant to Section 802.01B of the NYSE’s Listed Company Manual. Following redemptions that occurred in March 2023, GigCapital5 had fallen below the NYSE’s continued listing standard requiring a listed acquisition company to maintain an average aggregate global market capitalization attributable to its publicly-held shares over a consecutive 30 trading day pe”

Apexigen, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“April 11, 2023, Apexigen, Inc. (the “Company”) received a written notice from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it has not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for a period of 30 consecutive business days (the “Notice”). This Notice has no immediate effect on the listing of the Company’s stock on the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company is provided a compliance period of 180 calendar days from the date of the Notice”

Unique Fabricating, Inc. received a nyse_american deficiency notice notice regarding late filing (rules 1007).

“April 6, 2023, Unique Fabricating, Inc. (the “Company”) received a notice letter (the “Notice”) from the NYSE Regulation Department (the “Staff”) notifying the Company that, based upon the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report”) by the filing due date, March 31, 2023 (the “Filing Delinquency”), it was not in compliance with the New York Stock Exchange American’s continued listing requirements. The Company is now subject to the procedures and requirements set forth in Section 1007 of the New York Stock Exc”

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy Nasdaq Marketplace Rule 5550(b)(1). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. In”

Hempacco Co., Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 6, 2023, Hempacco Co., Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “ Bid Price Requirement ”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price o”

Cycurion, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the Company’s Minimum Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on the Nasdaq Global Market pursuant to Nasdaq listing rule 5450(b)(2)(A). The Notice has no immediate effect on the listing of the Company’s common stock, warrants and units, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbols “WAVS,” “WAVSW” and “WAVSU,” respectively. In accordance with Nasdaq listing rule 5810(c”

Royalty Management Holding Corp received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“April 4, 2023, American Acquisition Opportunity Inc. (the “Company”) received a letter (the “MVLS Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Minimum Market Value of Listed Securities (“MVLS”) was less than $35 million, which does not meet the requirement for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with Nasdaq Listing Rule 581”

NORTHERN REVIVAL ACQUISITION Corp received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“April 4, 2023, Northern Revival Acquisition Corporation (the “Company”) received a letter (the “MVLS Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the MVLS Notice, the Company’s Minimum Market Value of Listed Securities (“MVLS”) was less than $35.0 million, which does not meet the requirement for continued listing on The Nasdaq Capital Market, as required by Nasdaq Listing Rule 5550(b)(2) (the “MVLS Rule”). In accordance with Nasdaq Listing Rul”

Latch, Inc. received a nasdaq hearing update notice regarding late filing (rules 5250(c)(1)).

“April 6, 2023, the Company received an additional notice from the Staff (the “April Notice”) notifying the Company that it is not in compliance with the Listing Rule as a result of its failure to timely file the Annual Report with the SEC. The April Notice has no immediate effect on the listing or trading of the Company’s shares of common stock or warrants. However, if the Company fails to regain compliance with the Listing Rule by August 4, 2023, the Company’s shares of common stock and warrants will be subject to delisting from Nasdaq. There can be no assurances that the Company will be able”

GELESIS HOLDINGS, INC. received a nyse delisting notice notice regarding market value (rules 802.01B).

“April 10, 2023. NYSE Regulation reached its decision to delist these securities pursuant to Section 802.01B of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at least $15,000,000. The Company does not intend to appeal the delisting determination. The Company anticipates that its common stock identified above will be traded in the over-the-counter (“OTC”) market commencing on April 11, 2023. The common stock will”

CEA Industries Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 10, 2023, CEA Industries Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between February 24, 2023, through April 6, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days”

ESPORTS ENTERTAINMENT GROUP, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“April 6, 2023, Esports Entertainment Group, Inc. (the “Company”) received a notice from The Nasdaq Stock Market LLC’s (“Nasdaq”) Hearings Panel (the “Panel”), that the Panel had granted the Company an extension until April 30, 2023, to demonstrate compliance with the $2,500,000 stockholders’ equity requirement, as outlined in Listing Rule 5550(b)(1). The Company is in the process of taking definitive steps to comply with this and all applicable conditions and criteria for continued listing on Nasdaq. There can be no assurances, however, that the Company will be able to do so. The Company must”

BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 10, 2023 Nasdaq Notice On April 10, 2023, the Company received notice (the “Bid Price Notice”) from Nasdaq advising the Company that for 30 consecutive trading days preceding the date of the Bid Price Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company has 180 calendar days from the date of the Bid Price Notice to regain compliance with the Minimum Bid Price Requirement. If at any time during”

BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 6, 2023 Nasdaq Notice On April 6, 2023, Bellicum Pharmaceuticals, Inc. (the “Company”) received notice (the “Stockholder’s Equity Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1). The Company has 45 calendar days from the date of the Stockholders’ Equity Notice to submit to Nasdaq a plan to regain compliance. The Company is currently eval”

Tingo Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“April 3, 2023, Tingo Group, Inc., a Delaware corporation (the “Company”), received a staff deficiency notice (the “Nasdaq Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) informing the Company that its common stock, par value $0.001 per share, failed to comply with the $1.00 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The Nasdaq Notification Letter advised the Company that, based upon the closing bid price during the period from February 14, 2023 to March 28, 2023, the Company no longer meets this test. Pursua”